Article
Flavonoids from Siparuna cristata as Potential Inhibitors of SARS‑CoV‑2 Replication
Registro en:
LEAL, Carla Monteiro et al. Flavonoids from Siparuna cristata as Potential Inhibitors of SARS‑CoV‑2 Replication. Revista Brasileira de Farmacognosia, p . 1 - 9, July 2021.
1981-528X
10.1007/s43450-021-00162-5
Autor
Leal, Carla Monteiro
Leitão, Suzana Guimarães
Sausset, Romain
Mendonça, Simony C.
Nascimento, Pedro H. A.
Cheohen, Caio Felipe de Araujo R.
Esteves, Maria Eduarda A.
Silva, Manuela Leal da
Gondim, Tayssa Santos
Monteiro, Maria Eduarda S.
Tucci, Amanda Resende
Fintelman‑Rodrigues, Natália
Siqueira, Marilda Agudo Mendonça Teixeira de
Miranda, Milene Dias
Costa, Fernanda N.
Simas, Rosineide C.
Leitão, Gilda Guimarães
Resumen
The novel coronavirus SARS-CoV-2 has been affecting the world, causing severe pneumonia and acute respiratory syndrome,
leading people to death. Therefore, the search for anti-SARS-CoV-2 compounds is pivotal for public health. Natural products
may present sources of bioactive compounds; among them, flavonoids are known in literature for their antiviral activity.
Siparuna species are used in Brazilian folk medicine for the treatment of colds and flu. This work describes the isolation of
3,3′,4′-tri-O-methyl-quercetin, 3,7,3′,4′-tetra-O-methyl-quercetin (retusin), and 3,7-di-O-methyl-kaempferol (kumatakenin)
from the dichloromethane extract of leaves of Siparuna cristata (Poepp. & Endl.) A.DC., Siparunaceae, using high-speed
countercurrent chromatography in addition to the investigation of their inhibitory effect against SARS-CoV-2 viral replication.
Retusin and kumatakenin inhibited SARS-CoV-2 replication in Vero E6 and Calu-3 cells, with a selective index greater
than lopinavir/ritonavir and chloroquine, used as control. Flavonoids and their derivatives may stand for target compounds
to be tested in future clinical trials to enrich the drug arsenal against coronavirus infections.